Roche Shares Dip as Alzheimer's Treatment Falls Short in Phase 3 Trials
November 14 2022 - 4:09AM
Dow Jones News
By Joshua Kirby
Shares in Swiss drug maker Roche Holding AG slid in early trade
Monday after Phase 3 studies of a candidate Alzheimer's treatment
failed to meet their primary endpoints.
At 0830 GMT, shares traded 4.4% lower at 311.15 Swiss
francs.
In two Phase 3 studies, Roche's gantenerumab--a proposed
treatment for sufferers of early Alzheimer's disease--didn't meet
their primary endpoint of slowing clinical decline, Roche said.
Compared against placebos, the drug showed no statistically
significant effect in the two studies, the company said.
Despite the results weighing on investor sentiment,
gantenerumab's failure was likely widely assumed, and longer-term
buyers of the stock should mitigate losses, analysts at Jefferies
said in a note following the news.
Roche said it will keep working on novel diagnostics and
treatments for Alzheimer's.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
November 14, 2022 03:54 ET (08:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
